Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M UNGER

Showing results (521-530 of 604) with videos related to

Pageof 61
Sort By:
NEJM Evidence|February 6, 2024
Transdermal Nicotine Treatment and Progression of Early Parkinson's DiseaseWolfgang H Oertel, Hans-Helge Müller, Marcus M Unger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapyCarol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.
Journal of Comparative Effectiveness Research|March 6, 2013
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement processPatricia A Deverka, Danielle C Lavallee, Priyanka J Desai, et al.
Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.
Oncotarget|August 25, 2016
CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumorsKhalil Ahmed, Betsy T Kren, Md Joynal Abedin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology GroupVernon K Sondak, P-Y Liu, Ralph J Tuthill, et al.
Genomics, Proteomics & Bioinformatics|November 28, 2021
Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD TrialAnouck Becker, Georges Pierre Schmartz, Laura Gröger, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 19, 2007
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphomaRobin A Roberts, Constantine M Sabalos, Michael L LeBlanc, et al.
Journal of Cancer Research and Clinical Oncology|June 8, 1999
Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trialK A Margolin, P Y Liu, J M Unger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment StudiesJoseph M Unger, Michael LeBlanc, Suzanne George, et al.
Pageof 61

Showing results (521-530 of 604) with videos related to

Sort By:
Pageof 61
NEJM Evidence|February 6, 2024
Transdermal Nicotine Treatment and Progression of Early Parkinson's DiseaseWolfgang H Oertel, Hans-Helge Müller, Marcus M Unger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapyCarol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.
Journal of Comparative Effectiveness Research|March 6, 2013
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement processPatricia A Deverka, Danielle C Lavallee, Priyanka J Desai, et al.
Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.
Oncotarget|August 25, 2016
CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumorsKhalil Ahmed, Betsy T Kren, Md Joynal Abedin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology GroupVernon K Sondak, P-Y Liu, Ralph J Tuthill, et al.
Genomics, Proteomics & Bioinformatics|November 28, 2021
Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD TrialAnouck Becker, Georges Pierre Schmartz, Laura Gröger, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 19, 2007
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphomaRobin A Roberts, Constantine M Sabalos, Michael L LeBlanc, et al.
Journal of Cancer Research and Clinical Oncology|June 8, 1999
Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trialK A Margolin, P Y Liu, J M Unger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment StudiesJoseph M Unger, Michael LeBlanc, Suzanne George, et al.
Pageof 61